Current TB Tests Fail Those Who Need Them Most.

Current latent tuberculosis infection tests do not perform well for those patients that need them the most. The higher the risk a patient has to develop active tuberculosis due to its immunologic deficiencies, the lower the performance of current tests.

Tuberculosis remains a major global health challenge. While incidence in Europe is relatively low compared to other regions, maintaining this low level and moving toward elimination relies on continued and effective testing.

Globally, an estimated 1 in 4 people and in Europe 1 of the 7 people carry latent tuberculosis infection – harboring the bacteria without showing symptoms [1]. This substantial latent reservoir poses a persistent risk for future active tuberculosis cases, particularly among vulnerable groups such as immunocompromised patients, who face up to a 10% higher likelihood of progression to active disease [2].

Tuberculosis is NOT eradicated as testing stays of high importance

Current latent tuberculosis infection tests do not perform well for those patients that need them the most

Clinical need confirmed by KOLs and guidelines²
“Be aware of the risk of false negative test autcome”

~4,5k overall healthcare costs per false negative patient in high burden countries³

Significant resources are dedicated to Latent TBI testing in the European Union, with the market for existing tests generating approximately €250 million in revenue and expected to grow at a CAGR of 4.5% from 2025 to 2033 [3].

Despite these investments, current diagnostic tests have critical limitations. Their performance is particularly suboptimal in the populations that most urgently require accurate detection—immunocompromised individuals. In these patients, weakened immune responses can reduce test sensitivity, increasing the risk of missed or delayed diagnoses and hindering tuberculosis control efforts. In the Netherlands alone, over 200,000 immunocompromised patients are affected. For example, sensitivity in chronic kidney disease patients has been reported to be below 53% [4]. The issue of inaccurate test outcomes for immunocompromised patients is also explicitly highlighted in clinical guidelines [5].

ProliSpot-Tuberculosis test

The ProliSpot-Tuberculosis test can measure T-cell responses more accurate than currently used test methods.

The key innovation of ProliSpot-Tuberculosis lies in its measurement principle. Unlike IGRA tests, which indirectly measure cytokines released by a subset of T cells, ProliSpot-Tuberculosis directly detects antigen-specific proliferation of all tuberculosis reactive T cells. This results in a single cell resolution which is a more robust and accurate immune readout, particularly in patients with impaired immune function, thereby reducing false-negative and indeterminate results and minimizing the need for repeat testing.

Mission & Vision

Mission & Vision

Limosa Immunodiagnostics B.V. is the ‘’home of the ProliSpot-Technology’’: a novel, highly sensitive platform for antigen-specific T cell diagnostics. The company’s mission is that not a single patient should die from the lack of diagnostic sensitivity. Our vision is to establish ProliSpot as a broadly applicable, clinically impactful and commercially scalable diagnostic platform for immune diagnostics across infectious diseases, oncology, and immune monitoring, starting with applications that address clear unmet medical needs

Team

Daphne Gengler, MSc

CEO

With over 12 years of experience in MedTech startup management and medical device product development, Daphne is a seasoned entrepreneur and co-founder dedicated to advancing healthcare innovation. Holding an M.Sc. in Biomechanical Engineering, she combines deep technical expertise with strategic leadership to bring transformative medical technologies from concept to market. Passionate about bridging engineering and patient care, Daphne thrives on creating solutions that improve lives.

Geert van den Bogaart, Prof. Dr,

CMO

Geert is an accomplished immunology researcher with more than 20 years of experience, committed to translating scientific discoveries into meaningful real-world impact. As an inventor and founder, he bridges academic excellence with entrepreneurial vision. He holds a PhD in Biology and serves as Professor of Molecular Immunology at the University of Groningen, leading innovative research at the forefront of immune-mediated diseases.

Frans Bianchi, Dr.

CTO

With over 15 years of experience in assay research and development, he is an expert in translating complex biological insights into robust diagnostic solutions. As an inventor and founder, he combines scientific innovation with an entrepreneurial drive to bring novel technologies to market. He holds a PhD in Biochemistry and serves as Assistant Professor of Molecular Immunology, contributing to cutting-edge research in immune-based diagnostics.

Rinse de Boer, BSc

Senior laboratory technician

Rinse brings more than 15 years of hands-on expertise in assay development and R&D, focusing on the design and optimization of innovative diagnostic solutions. His strong technical expertise is grounded in a B.Sc. in Medical and Molecular Biology, providing a solid foundation in both clinical and molecular sciences. He is dedicated to advancing reliable, high-quality assays that translate scientific insight into practical healthcare applications.